Ebola Virüsü Hastalığı

Kiley MP, Bowen ET, Eddy GA, et al. Filoviridae: a taxonomic home for Marburg and Ebola viruses?. Intervirology. 1982;18(1-2):24-32. doi:10.1159/000149300

Kuhn JH, Amarasinghe GK, Basler CF, et al. ICTV Virus Taxonomy Profile: Filoviridae. J Gen Virol. 2019;100(6):911-912. doi:10.1099/jgv.0.001252

Siegert R, Shu HL, Slenczka W, Peters D, Müller G. Zur Atiologie einer umbekannten, von Affen ausgegangenen menschlichen Infektionskrankheit [On the etiology of an unknown human infection originating from monkeys]. Dtsch Med Wochenschr. 1967;92(51):2341-2343. doi:10.1055/s-0028-1106144

Emanuel J, Marzi A, Feldmann H. Filoviruses: Ecology, Molecular Biology, and Evolution. Adv Virus Res. 2018;100:189-221. doi:10.1016/bs.aivir.2017.12.002

Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019;17(10):593-606. doi:10.1038/s41579-019-0233-2

Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The Pathogenesis of Ebola Virus Disease. Annu Rev Pathol. 2017;12:387-418. doi:10.1146/annurev-pathol-052016-100506

Munster VJ, Bausch DG, de Wit E, et al. Outbreaks in a rapidly changing Central Africa — lessons from Ebola. N Engl J Med 2018;379:1198-201.

Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009;5(7):e1000536.

Olival KJ, Hayman DT. Filoviruses in bats: current knowledge and future direc- tions. Viruses 2014;6:1759-88.

Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 2015;235:153- 74.

Hoenen T, Shabman RS, Groseth A, et al. Inclusion bodies are a site of ebolavirus replication. J Virol. 2012;86(21):11779-11788. doi:10.1128/JVI.01525-12

Falasca L, Agrati C, Petrosillo N, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250-1259. doi:10.1038/cdd.2015.67

Jagadesh S, Sevalie S, Fatoma R, et al. Disability Among Ebola Survivors and Their Close Contacts in Sierra Leone: A Retrospective Case-Controlled Cohort Study. Clin Infect Dis. 2018;66(1):131-133. doi:10.1093/cid/cix705

Vetter P, Fischer WA II, Schibler M, acobs M, Bausch DG, Kaiser L. Ebola vi- rus shedding and transmission: review of current evidence. J Infect Dis 2016;214: Suppl 3:S177-S184.

Sissoko D, Keïta M, Diallo B, et al. Ebola virus persistence in breast milk af- ter no reported illness: a likely source of virus transmission from mother to child. Clin Infect Dis 2017;64:513-6.

Diallo B, Sissoko D, Loman NJ, et al. Resurgence of Ebola virus in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin Infect Dis 2016;63:1353-6.

Leligdowicz A, Fischer WA 2nd, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care. 2016;20(1):217. Published 2016 Jul 29. doi:10.1186/s13054-016-1325-2

McElroy A. Understanding bleeding in ebola virus disease. Clin Adv Hematol Oncol. 2015;13(1):29-31.

Nicastri E, Kobinger G, Vairo F, et al. Ebolavirusdisease:epidemiology,clini- cal features, management, and preven- tion. Infect Dis Clin North Am 2019;33: 953-76.

Shi M, Lin XD, Chen X, et al. The evo- lutionary history of vertebrate RNA vi- ruses. Nature 2018;556:197-202.

Emanuel J, Marzi A, Feldmann H. Filoviruses: Ecology, Molecular Biology, and Evolution. Adv Virus Res. 2018;100:189-221. doi:10.1016/bs.aivir.2017.12.002

Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol 2019; 17:593-606.

Olival KJ, Hayman DT. Filoviruses in bats: current knowledge and future direc- tions. Viruses 2014;6:1759-88.

Frick WF, Kingston T, Flanders J. A review of the major threats and challenges to global bat conservation. Ann N Y Acad Sci. 2020;1469(1):5-25. doi:10.1111/nyas.14045

Wonderly B, Jones S, Gatton ML, et al. Comparative performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014-2016 Ebola epidemic in West Africa. PLoS One 2019;14(3):e0212113.

Tembo J, Simulundu E, Changula K, et al. Recent advances in the development and evaluation of molecular diagnostics for Ebola virus disease. Expert Rev Mol Diagn 2019. https://doi.org/10.1080/14737159.2019.1595592.

Coarsey CT, Esiobu N, Narayanan R, Pavlovic M, Shafiee H, Asghar W. Strategies in Ebola virus disease (EVD) diagnostics at the point of care. Crit Rev Microbiol. 2017;43(6):779-798. doi:10.1080/1040841X.2017.1313814.

Shorten RJ, Brown CS, Jacobs M, Rat- tenbury S, Simpson AJ, Mepham S. Diag- nostics in Ebola virus disease in resource- rich and resource-limited settings. PLoS Negl Trop Dis 2016;10(10):e0004948.

Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 2016;374:636-46.

Case definition recommendations for Ebola or Marburg virus diseases. Geneva: World Health Organization, August 9, 2014(https://apps.who.int/iris/bitstream/ handle/10665/146397/WHO_EVD_CaseDef _14.1_eng.pdf ?sequence=1).

31.Feldmann H, Sprecher A, Geisbert TW. Ebola. N Engl J Med. 2020;382(19):1832-1842. doi:10.1056/NEJMra1901594

Clément C, Adhikari NKJ, Lamontagne F. Evidence-Based Clinical Management of Ebola Virus Disease and Epidemic Viral Hemorrhagic Fevers. Infect Dis Clin North Am. 2019;33(1):247-264. doi:10.1016/j.idc.2018.10.013

Nicastri E, Kobinger G, Vairo F, et al. Ebola Virus Disease: Epidemiology, Clinical Features, Management, and Prevention. Infect Dis Clin North Am. 2019;33(4):953-976. doi:10.1016/j.idc.2019.08.005

Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of ebola virus dis- ease in the United States and Europe. N Engl J Med 2016;374(7):636–46.

Langer M, Portella G, Finazzi S, et al. Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa. Intensive Care Med. 2018;44(8):1266-1275. doi:10.1007/s00134-018-5308-4

Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea [published correction appears in PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D’Ortenzio, Eric]] [published correction appears in PLoS Med. 2016 Jun;13(6):e1002066]. PLoS Med. 2016;13(3):e1001967. Published 2016 Mar 1. doi:10.1371/journal.pmed.1001967.

PREVAIL II Writing Group, Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016;375(15):

1448–56.

The PREVAIL II Writing Group for the Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016; 375:1448-56.

Bornholdt ZA, Herbert AS, Mire CE, et al. A two-antibody pan-Ebolavirus cock- tail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe 2019;25(1):49-58.e5.

Brannan JM, He S, Howell KA, et al. Post-exposure immunotherapy for two ebolaviruses and Marburg virus in non- human primates. Nat Commun 2019;10: 105.

Bornholdt ZA, Herbert AS, Mire CE, et al. A two-antibody pan-Ebolavirus cock- tail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe 2019;25(1):49-58.e5.

Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016;374:1647–60.

CDC Centers for Disease Control and Prevention Guidance for Donning and Doffing Personal Protective Equipment (PPE) during management of patients with Ebola Virus Disease in U.S. Hospitals. Available at: www.cdc.gov/vhf/ ebola/hcp/ppe-training/index.html. Accessed March 1, 2019.

Mumma JM, Durso FT, Ferguson AN, et al. Human Factors Risk Analyses of a Doffing Protocol for Ebola-Level Personal Protective Equipment: Mapping Errors to Contamination. Clin Infect Dis. 2018;66(6):950-958. doi:10.1093/cid/cix957

Roberts V. To PAPR or not to PAPR?. Can J Respir Ther. 2014;50(3):87-90.